SI-BONE INC (SIBN) Stock Price, Forecast & Analysis
NASDAQ:SIBN • US8257041090
SIBN Key Statistics, Chart & Performance
The current stock price of SIBN is 15.35 USD. In the past month the price decreased by -14.11%. In the past year, price decreased by -8.6%.
SIBN Technical Analysis
SIBN Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SIBN. SIBN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SIBN Financial Highlights
Over the last trailing twelve months SIBN reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 44.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.29% | ||
| ROE | -12.64% | ||
| Debt/Equity | 0.21 |
SIBN Forecast & Estimates
15 analysts have analysed SIBN and the average price target is 25.91 USD. This implies a price increase of 68.78% is expected in the next year compared to the current price of 15.35.
For the next year, analysts expect an EPS growth of 28.9% and a revenue growth 20.26% for SIBN
SIBN Ownership
SIBN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.56 | 193.832B | ||
| ISRG | INTUITIVE SURGICAL INC | 48.07 | 169.664B | ||
| SYK | STRYKER CORP | 24.57 | 139.908B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.52 | 109.921B | ||
| BDX | BECTON DICKINSON AND CO | 11.24 | 50.66B | ||
| IDXX | IDEXX LABORATORIES INC | 42.72 | 49.283B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.85 | 44.358B | ||
| RMD | RESMED INC | 20.65 | 35.869B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.21 | 35.845B | ||
| DXCM | DEXCOM INC | 27.98 | 25.383B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SIBN
Company Profile
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Company Info
SI-BONE INC
471 El Camino Real, Suite 101
Santa Clara CALIFORNIA 95050 US
CEO: Jeffrey W. Dunn
Employees: 349
Phone: 14082070700
SI-BONE INC / SIBN FAQ
What does SIBN do?
SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Can you provide the latest stock price for SI-BONE INC?
The current stock price of SIBN is 15.35 USD. The price increased by 2.47% in the last trading session.
Does SI-BONE INC pay dividends?
SIBN does not pay a dividend.
What is the ChartMill rating of SI-BONE INC stock?
SIBN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for SI-BONE INC?
SI-BONE INC (SIBN) has a market capitalization of 666.04M USD. This makes SIBN a Small Cap stock.
What is the next earnings date for SIBN stock?
SI-BONE INC (SIBN) will report earnings on 2026-02-23, after the market close.